Salix Pharmaceuticals presents Xifaxan monotherapy vs lactulose for OHE recurrence and mortality at ACG 2024 Annual Scientific Meeting.

Salix Pharmaceuticals, a subsidiary of Bausch Health, will present findings at the ACG 2024 Annual Scientific Meeting. The research includes a post-hoc analysis comparing Xifaxan® (rifaximin) monotherapy and lactulose for reducing overt hepatic encephalopathy (OHE) recurrence and mortality. Additionally, new data on Xifaxan's effect on rehospitalizations after OHE discharge will be shared. The meeting will also feature findings on Plenvu, a bowel preparation medication.

October 27, 2024
8 Articles